Latest Racura Oncology News

Page 1 of 2
Racura Oncology has appointed Beyond Drug Development to oversee its HARNESS-1 Phase 1a/b trial combining RC220 with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward clinical advancement.
Ada Torres
Ada Torres
24 Dec 2025
Race Oncology has raised $3.22 million through a private placement to fund its HARNESS-1 Phase 1a/b trial targeting non-small cell lung cancer, with patient enrolment expected early next year.
Ada Torres
Ada Torres
9 Dec 2025
Race Oncology has received a $2.8 million Australian R&D tax refund for FY2025, with further overseas R&D rebates expected, bolstering its clinical development of innovative cancer therapies.
Ada Torres
Ada Torres
27 Nov 2025
Race Oncology has received ethics approval to launch its HARNESS-1 Phase 1a/b trial testing RC220 combined with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward addressing resistance to current therapies.
Ada Torres
Ada Torres
26 Nov 2025
Race Oncology Limited has secured shareholder approval for a replacement Constitution at its 2025 Annual General Meeting, updating its corporate governance framework to align with current regulatory standards.
Ada Torres
Ada Torres
24 Nov 2025
Race Oncology has announced pivotal new clinical trials for its lead asset RC220, aiming to accelerate regulatory approval in Acute Myeloid Leukemia and tackle resistance in Non-Small Cell Lung Cancer.
Ada Torres
Ada Torres
17 Nov 2025
Race Oncology has filed pivotal patents on the active (E,E)-bisantrene isomer, potentially extending its drug exclusivity by two decades, while advancing its Phase 1 clinical trial and maintaining a strong cash position.
Ada Torres
Ada Torres
31 Oct 2025
Race Oncology showcased compelling preclinical data at ESMO 2025 revealing that their drug RC220, combined with doxorubicin, not only shields the heart from toxicity but also boosts anticancer effects, supporting ongoing clinical trials.
Ada Torres
Ada Torres
20 Oct 2025
(E,E)-bisantrene, Race Oncology’s lead anticancer candidate, operates by binding to G4-DNA and RNA structures, revealing a novel mechanism that disrupts key cancer drivers including the MYC gene.
Ada Torres
Ada Torres
2 Oct 2025
Race Oncology has secured Investigational New Drug approval from South Korea’s regulatory authority, enabling Phase 1 clinical trials of RC220 in combination with doxorubicin for solid tumour patients across four Korean sites.
Ada Torres
Ada Torres
24 Sept 2025
Race Oncology has uncovered that its anticancer drug bisantrene exists as three light-sensitive isomers, with only one showing potent activity. The company has filed patents to protect this active form, potentially extending its intellectual property rights until 2045.
Ada Torres
Ada Torres
16 Sept 2025
Race Oncology has activated its first clinical trial site in Hong Kong for the Phase 1 study of RC220 combined with doxorubicin in advanced solid tumours, marking a significant step in accelerating patient enrolment and broadening clinical data.
Ada Torres
Ada Torres
2 Sept 2025